Health care startups in Asia
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Even Healthcare | Bangalore | Series B | $50.0M | 2026-10-19 |
| Lumen | Tel Aviv | Series B | $62.0M | 2022-12-01 |
| CureBay | Bhubaneshwar | Series C | $7.3M | 2026-10-22 |
| Aidoc | Tel Aviv | Series E | $150.0M | 2026-04-29 |
| Practo | Bangalore | Series D | $32.0M | 2020-08-15 |
| Remepy | Ramat Gan | Series A | $36.0M | 2026-08-12 |
| Hypershell | Shenzhen | Series B | $50.0M | 2026-05-18 |
| Nua | Mumbai | Series C | $50.0M | 2026-09-07 |
8 rows of the CSV in 5 of its 18 columns.
- The 7,291 health care startups in Asia have raised $75.3B in total.
- 886 of them closed their most recent round in the last 12 months, $9.0B combined.
- The largest of those rounds is CORXEL Pharmaceuticals' $287.0M Series D, dated January 2026.
- The most recent is Shanghai Peptide Biotechnology's $140K seed round on 10 November 2026.
- TIPS Program is an investor in 61 of them, more than any other fund.
- Biotech is the most common other sector, with 2,017 companies (28%).
- 34% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (42% of companies with a recorded size).
- 5 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 7,291| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi, China | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| Tushen Zhihe | Tushen Zhihe provides artificial intelligence protein design services. | Artificial intelligence | Minhang, China | Seed | $1.4M | 2026-11-09 | $1.5M | Wuxi Capital, CHENGMEI VENTURES | 11 to 50 | 2023 |
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai, China | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| BionicM | BionicM develops high-performance robotic prostheses that improve mobility for people with disabilities. | Hardware | Tokyo, Japan | Series B | $4.5M | 2026-11-02 | $15.5M | UTEC - The University of Tokyo Edge Capital Partners, UTokyo Innovation Platform, Shinsei Corporate Investment +1 | 11 to 50 | 2018 |
| CHOSEN by Dermatology | CHOSEN by Dermatology develops clinical skincare, haircare, and wellness products for skin concerns. | Health care | Chennai, India | Series A | $5.0M | 2026-10-28 | $6.3M | Peak XV Partners | 51 to 100 | 2020 |
| Troovy | Troovy makes nutritious foods using natural, wholesome ingredients. | Health care | Gurgaon, India | Series B | $10.5M | 2026-10-27 | $18.5M | Veltis Capital | 11 to 50 | 2021 |
| CureBay | CureBay provides healthcare, telemedicine, diagnostics, and pharmacy services. | Artificial intelligence | Bhubaneshwar, India | Series C | $7.3M | 2026-10-22 | $45.1M | Elevar Equity | 501 to 1,000 | 2021 |
| Even Healthcare | Even is a health-tech company and healthcare provider partnering directly with top hospitals in India. | Fintech | Bangalore, India | Series B | $50.0M | 2026-10-19 | $140.9M | Khosla Ventures, Founders Fund, 8VC +2 | 101 to 250 | 2020 |
| My Benefit | My Benefit offers a digital platform for tracking musculoskeletal conditions and fitness levels. | Health care | Seocho, South Korea | Series A | $2.3M | 2026-10-19 | $5.3M | We Ventures | 11 to 50 | 2005 |
| Caredoc | Caredoc runs an online platform that provides information on proven elderly care facilities. | Health care | Gangneung, South Korea | Series C | $39.3M | 2026-10-15 | $113.3M | TIPS Program, Korea Credit Guarantee Fund, Lotte Ventures | 11 to 50 | 2018 |
| Hyperway Pharm | Hyperway Pharm conducts pharmaceutical research, development, and production. | Health care | Chengdu, China | Series B | $14.9M | 2026-10-15 | $56.8M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, Huaige Capital +1 | 51 to 100 | 2019 |
| Aibo Medical Robot | Aibo Medical Robot researches and develops robots for vascular interventional surgery. | Hardware | Shenzhen, China | Series A | $14.1M | 2026-10-15 | $33.0M | Lenovo Capital and Incubator Group (LCIG), CDH Investments, Long Hill Capital +2 | 2020 | |
| Haimikang Intelligence | Haimikang Intelligence develops brain-computer interfaces and exoskeleton medical products. | Health care | Putuo, China | Seed | $1.4M | 2026-10-15 | $1.4M | New Access Capital | 51 to 100 | 2020 |
| Salary Hero | Salary Hero provides a financial health platform for employees. | Fintech | Bangkok, Thailand | Series A | $7.6M | 2026-10-14 | $10.4M | 500 Global, Global Founders Capital, 500 TukTuks +2 | 11 to 50 | 2021 |
| Nat Habit | Nat Habit is a beauty and wellness brand that sells natural skincare products. | Health care | Gurgaon, India | Series C | $14.7M | 2026-10-10 | $30.9M | Titan Capital, Surge, Whiteboard Capital +1 | 101 to 250 | 2018 |
| Sunfox Technologies | Sunfox Technologies operates a research and development lab focused on accessible technology. | Hardware | Dehra Dun, India | Series A | $7.0M | 2026-10-07 | $9.5M | Venture Catalysts, LVX Ventures, Mumbai Angels | 101 to 250 | 2016 |
| Celaid Therapeutics | Celaid Therapeutics develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders. | Biotech | Tokyo, Japan | Series B | $2.5M | 2026-10-05 | $17.1M | UTEC - The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, Joyo Capital Partners | 1 to 10 | 2020 |
| HITS | HITS develops artificial intelligence software for drug discovery and pharmaceutical research. | Artificial intelligence | Seoul, South Korea | Series B | $13.5M | 2026-09-28 | $25.1M | Korea Investment Partners, Capstone Partners, Company K Partners +2 | 11 to 50 | 2020 |
| Amaani | Amaani builds beauty and wellness brands from the Middle East, including its flagship brand AÏZA. | Health care | Dubai, United Arab Emirates | Series A | $5.0M | 2026-09-28 | $11.0M | Peak XV Partners | 1 to 10 | 2023 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai, China | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| Barty Medical | Barty Medical provides hospital healthcare services to patients. | Health care | Hangzhou, China | Series D | $29.5M | 2026-09-23 | $46.7M | Shenzhen Guozhong Venture Capital Management, Sinowisdom, Sunz Fund | 101 to 250 | 2015 |
| Apollon | Apollon develops noninvasive continuous glucose monitoring systems. | Artificial intelligence | Seoul, South Korea | Series A | $3.7M | 2026-09-22 | $6.4M | TIPS Program, KB Investment, TheVentures +2 | 11 to 50 | 2021 |
| Nutshell Therapeutics | Nutshell Therapeutics discovers small-molecule drugs using insights from protein dynamics. | Artificial intelligence | Shanghai, China | Series C | $40.0M | 2026-09-15 | $75.2M | Matrix Partners China, Source Code Capital, Northern Light Venture Capital +1 | 51 to 100 | 2013 |
| Josan-shes | Josan-shes is a web platform connecting women and families with nursing, babysitting, and childcare services. | Health care | Tokyo, Japan | Series A | $2.6M | 2026-09-15 | $3.6M | East Ventures, Partners Fund | 2021 | |
| QL Biopharma | QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. | Biotech | Beijing, China | Series C | $44.7M | 2026-09-14 | $173.7M | Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 | 101 to 250 | 2018 |
| Nua | Nua sells customizable sanitary products as part of its women's wellness and hygiene brand. | Commerce | Mumbai, India | Series C | $50.0M | 2026-09-07 | $66.5M | Kae Capital, Lightbox | 51 to 100 | 2017 |
| Medulance | Medulance offers a GPS-based platform for fast, reliable first-point medical attention. | Hardware | New Delhi, India | Series A | $2.5M | 2026-09-04 | $5.8M | Alkemi Growth Capital | 101 to 250 | 2016 |
| Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai, China | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
| Kossel Medical | Kossel Medical develops and manufactures vascular interventional devices and clinical system solutions. | Health care | Suzhou, China | Series C | $59.5M | 2026-09-01 | $103.0M | Fortune Venture Capital, Suzhou International Development Venture Capital, Ming Bioventures +1 | 501 to 1,000 | 2013 |
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou, China | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
Table 1. Health care startups in Asia: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 7,291.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Shanghai, China | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| 2 | Aidoc | Aidoc develops artificial intelligence software for healthcare imaging and clinical workflows. | Artificial intelligence | Tel Aviv, Israel | Series E | $150.0M | 2026-04-29 | $564.0M | General Catalyst, TCV, TLV Partners +2 | 251 to 500 | 2016 |
| 3 | New Radiomedicine Technology | New Radiomedicine Technology supplies medical isotopes in China. | Biotech | Chengdu, China | Series E | $145.4M | 2026-04-03 | $330.6M | Chengdu Science and Technology Venture Capital | 101 to 250 | 2016 |
| 4 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou, China | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 5 | Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Shanghai, China | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| 6 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi, China | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 7 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai, China | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 8 | Surgerii Technology | Surgerii Technology develops minimally invasive surgical robots. | Hardware | Haidian, China | Series D | $100.0M | 2025-12-31 | $100.0M | Shunwei Capital, SDIC Venture Capital, Shanghai Biomedical Industrial Equity Investment Fund +1 | 11 to 50 | 2014 |
| 9 | Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia, China | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| 10 | Zenitar | Zenitar conducts drug research and biomedical technology industrialization. | Biotech | Chengdu, China | Series C | $86.0M | 2026-01-12 | $155.7M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital | 51 to 100 | 2019 |
Table 2. Health care startups in Asia: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | TIPS Program | Startup incubator | Gangneung, South Korea | 61 | 1% | 6 | Caredoc, Apollon, Plco |
| 2 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 32 | 0% | 8 | AusperBio, Tianhu Technology, Prime Lifescience |
| 3 | Matrix Partners China | Venture capital firm | Beijing, China | 23 | 0% | 3 | Nutshell Therapeutics, Alioth, D3 Bio |
| 4 | Shenzhen Capital Group | Venture capital firm | Nanshan, China | 21 | 0% | 3 | Kai Medtech, MoleculeMind, MAXVAX |
| 5 | IDG Capital | Private equity firm | Beijing, China | 20 | 0% | 6 | Layerwave Bio, Diyingjia Technology, Haimai Medical |
| 6 | Antler | Venture capital firm | Singapore | 20 | 0% | 1 | Kubo Care |
| 7 | 500 Global | Startup accelerator | Palo Alto, United States | 19 | 0% | 2 | Salary Hero, Pandorum Technologies |
| 8 | BioVenture | Venture capital firm | Suzhou, China | 19 | 0% | 5 | AusperBio, Degron Therapeutics, AccuPulse |
| 9 | Y Combinator | Startup accelerator | Mountain View, United States | 18 | 0% | 1 | Morphle Labs |
| 10 | Turkey Development Fund | Fund of funds | Umraniye, Turkey | 18 | 0% | 1 | Viseur AI |
| 11 | Venture Catalysts | Startup incubator | Mumbai, India | 16 | 0% | 3 | Sunfox Technologies, Butterfly Learnings, Pee Safe |
| 12 | Korea Investment Partners | Private equity firm | Seoul, South Korea | 16 | 0% | 3 | HITS, LabInCube, MAXVAX |
| 13 | CDH Investments | Private equity firm | Kowloon City, Hong Kong | 16 | 0% | 2 | Aibo Medical Robot, HemaCell |
| 14 | Legend Capital | Venture capital firm | Beijing, China | 16 | 0% | 5 | Diyingjia Technology, Delova Biotech, Lingtai Krypton Biotechnology |
| 15 | Kakao Ventures | Venture capital firm | Seongnam, South Korea | 15 | 0% | 1 | Goi |
Table 3. Health care startups in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 2,017 | 28% | $33.8B |
| Software | 1,460 | 20% | $11.2B |
| Artificial intelligence | 646 | 9% | $6.2B |
| Hardware | 416 | 6% | $2.3B |
| Commerce | 345 | 5% | $2.7B |
| Fintech | 183 | 3% | $2.9B |
| Education | 159 | 2% | $373.5M |
| Energy | 26 | 0% | $359.9M |
| Cybersecurity | 17 | 0% | $30.0M |
Table 4. Health care startups in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Health care startups in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| China | 3,459 | 47% |
| India | 1,152 | 16% |
| South Korea | 889 | 12% |
| Japan | 402 | 6% |
| Israel | 399 | 5% |
| Singapore | 219 | 3% |
| Turkey | 136 | 2% |
| United Arab Emirates | 93 | 1% |
| Taiwan | 89 | 1% |
| Indonesia | 81 | 1% |
| Hong Kong | 72 | 1% |
| Saudi Arabia | 53 | 1% |
Table 6. Health care startups in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Health care startups in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 20 | 2% | $235.3M |
| October 2026 | 71 | 8% | $839.6M |
| September 2026 | 64 | 7% | $1.0B |
| August 2026 | 61 | 7% | $634.5M |
| July 2026 | 62 | 7% | $817.0M |
| June 2026 | 78 | 9% | $589.0M |
| May 2026 | 68 | 8% | $922.1M |
| April 2026 | 59 | 7% | $742.5M |
| March 2026 | 87 | 10% | $671.5M |
| February 2026 | 71 | 8% | $382.0M |
| January 2026 | 106 | 12% | $896.6M |
| December 2025 | 93 | 10% | $955.5M |
| November 2025 | 46 | 5% | $281.9M |
Table 8. Health care startups in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 747 | 10% | $7.8B |
| 2025 | 878 | 12% | $6.5B |
| 2024 | 822 | 11% | $3.6B |
| 2023 | 837 | 11% | $4.5B |
| 2022 | 891 | 12% | $7.4B |
| 2021 | 641 | 9% | $12.7B |
Table 9. Health care startups in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 680 | 10% |
| 2020 to 2022 | 1,749 | 25% |
| 2015 to 2019 | 2,822 | 40% |
| 2010 to 2014 | 1,200 | 17% |
| Before 2010 | 681 | 10% |
Table 10. Health care startups in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 1,551 | 25% |
| 11 to 50 | 2,581 | 42% |
| 51 to 100 | 874 | 14% |
| 101 to 250 | 612 | 10% |
| 251 to 500 | 272 | 4% |
| 501 to 1,000 | 139 | 2% |
| 1,001 to 5,000 | 95 | 2% |
| 5,001 to 10,000 | 12 | 0% |
| 10,001 or more | 15 | 0% |
Table 11. Health care startups in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its headquarters is in Asia. On 16 November 2026 that is 7,291 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 7,291 rows: 2,538 have no round amount, 0 no city and 2,867 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in Asia are on the list?
- 7,291, in the file dated 16 November 2026. 886 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 7,291 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 72 hours, $599.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.